- A Cancer Detection Test Fails in Major Study The New York Times
- Grail shares plummet after UK study raises doubts over cancer test's prospects Reuters
- Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint Fierce Biotech
- Grail shares plummet after cancer test falls short in three-year NHS study FirstWord Pharma
- This once-hot cancer-detection company’s stock got cut in half after a failed trial MarketWatch
LEGAL_NOTICE: This website acts solely as an automated content aggregator. We do not host, store, or upload any media shown above. All content is indexed via machine logic from external sources.